human iga2 antibody Search Results


92
Miltenyi Biotec antibody pe mouse anti human iga 2
Antibody Pe Mouse Anti Human Iga 2, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+iga2+antibody/IgA2+Antibody%2C+anti-human/10__7554_slash_elife__41641-316-48-55
Average 92 stars, based on 1 article reviews
antibody pe mouse anti human iga 2 - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier

99
NSJ Bioreagents human iga2 antibody
Human Iga2 Antibody, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+iga2+antibody/Human+IgA2+Antibody/custom%40r20184%4010%2E1590%2Fs0100-204x2014001000004
Average 99 stars, based on 1 article reviews
human iga2 antibody - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

92
OriGene 1a4 antibody
1a4 Antibody, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+iga2+antibody/Human+IgA2+(Fc+specific)+Mouse+Monoclonal+Antibody/pmc08862096-51-2-4
Average 92 stars, based on 1 article reviews
1a4 antibody - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier

96
Miltenyi Biotec anti iga
Anti Iga, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+iga2+antibody/IgA+Antibody%2C+anti-human/pmc12905349-44-0-3
Average 96 stars, based on 1 article reviews
anti iga - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

93
Miltenyi Biotec a iga apc
A Iga Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+iga2+antibody/IgA+Antibody%2C+anti-human%2C+REAfinity/pm35490556-54-44-47
Average 93 stars, based on 1 article reviews
a iga apc - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

90
Meridian Life Science human myeloma iga2 m(1) antibody
Figure 1. Biochemical characterization of <t>225-IgA2-d471</t> and 225-IgA2-wt antibody. ( A ) Antibody content in supernatants was analyzed by ELISA, and specific production rates were calculated. ( B ) Affinity-purified antibodies were separated by size exclusion to isolate monomeric antibodies. ( C1 ) Purity of antibodies was analyzed by denaturing SDS-PAGE stained with silver nitrate. ( C2 ) Formation of non-native aggregates was analyzed using native-PAGE stained with Coomassie. Proteins were transferred onto PVDF membranes and probed using polyclonal antibodies against κ- ( C3 ) or α-chain (C4). Lanes: (1) control IgA2, (2) 225-IgA2-wt, 3) 225-IgA2-d471. ( D ) 225-IgA2-wt and –d471 producing cells were transfected with a pIRESpuro3 plasmid encoding human J-chain to allow the formation of stable dimeric IgA. Proteins were transferred onto PVDF membranes and stained using polyclonal antibodies against human α-chain. Lanes: (1) control IgA2, (2) purified monomeric 225-IgA2-wt, (3) purified monomeric 225-IgA2-d471, (4) 225-IgA2-wt containing SUP from CHO cells transfected with human J chain, (5) 225-IgA2-d471 containing SUP from CHO cells transfected with human J chain, (6) purified dimeric 225-IgA2-wt. ( E ) The composition of freshly prepared (E1), two (E2) and four (E3) year old preparations of 225-IgA2-wt (lane 1) and 225-IgA2-d471 (lane 2) was analyzed by analytical size exclusion chromatography on a Superdex200 10 × 300 column. (E4) Relative areas under the curve (rAUC) of monomeric (F M , elution volumes 10‒14 ml) and polymeric (F P , elution volumes 6.5–10 ml) IgA were calculated. ( F ) Thermal stability was analyzed by incubating antibodies at denaturing temperatures and measuring maintenance of functionality in chromium release assays using A431 as targets and freshly isolated human PMN as effector cells. Results are presented as “mean ± SEM” of “relative specific lysis [%]” of three independent experiments.
Human Myeloma Iga2 M(1) Antibody, supplied by Meridian Life Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+iga2+antibody/human+myeloma+iga2+m+1++antibody/pmc03896607-114-1-11
Average 90 stars, based on 1 article reviews
human myeloma iga2 m(1) antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Absolute Biotech monoclonal anti-human iga2
Figure 1. Biochemical characterization of <t>225-IgA2-d471</t> and 225-IgA2-wt antibody. ( A ) Antibody content in supernatants was analyzed by ELISA, and specific production rates were calculated. ( B ) Affinity-purified antibodies were separated by size exclusion to isolate monomeric antibodies. ( C1 ) Purity of antibodies was analyzed by denaturing SDS-PAGE stained with silver nitrate. ( C2 ) Formation of non-native aggregates was analyzed using native-PAGE stained with Coomassie. Proteins were transferred onto PVDF membranes and probed using polyclonal antibodies against κ- ( C3 ) or α-chain (C4). Lanes: (1) control IgA2, (2) 225-IgA2-wt, 3) 225-IgA2-d471. ( D ) 225-IgA2-wt and –d471 producing cells were transfected with a pIRESpuro3 plasmid encoding human J-chain to allow the formation of stable dimeric IgA. Proteins were transferred onto PVDF membranes and stained using polyclonal antibodies against human α-chain. Lanes: (1) control IgA2, (2) purified monomeric 225-IgA2-wt, (3) purified monomeric 225-IgA2-d471, (4) 225-IgA2-wt containing SUP from CHO cells transfected with human J chain, (5) 225-IgA2-d471 containing SUP from CHO cells transfected with human J chain, (6) purified dimeric 225-IgA2-wt. ( E ) The composition of freshly prepared (E1), two (E2) and four (E3) year old preparations of 225-IgA2-wt (lane 1) and 225-IgA2-d471 (lane 2) was analyzed by analytical size exclusion chromatography on a Superdex200 10 × 300 column. (E4) Relative areas under the curve (rAUC) of monomeric (F M , elution volumes 10‒14 ml) and polymeric (F P , elution volumes 6.5–10 ml) IgA were calculated. ( F ) Thermal stability was analyzed by incubating antibodies at denaturing temperatures and measuring maintenance of functionality in chromium release assays using A431 as targets and freshly isolated human PMN as effector cells. Results are presented as “mean ± SEM” of “relative specific lysis [%]” of three independent experiments.
Monoclonal Anti Human Iga2, supplied by Absolute Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+iga2+antibody/monoclonal+mouse+anti+human+iga2+antibody++nordic+immunological+laboratories+/pmc01809616-116-18-24
Average 90 stars, based on 1 article reviews
monoclonal anti-human iga2 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
ICN Biomedicals non-conjugated anti-human iga2 monoclonal antibodies (mabs)
Figure 1. Biochemical characterization of <t>225-IgA2-d471</t> and 225-IgA2-wt antibody. ( A ) Antibody content in supernatants was analyzed by ELISA, and specific production rates were calculated. ( B ) Affinity-purified antibodies were separated by size exclusion to isolate monomeric antibodies. ( C1 ) Purity of antibodies was analyzed by denaturing SDS-PAGE stained with silver nitrate. ( C2 ) Formation of non-native aggregates was analyzed using native-PAGE stained with Coomassie. Proteins were transferred onto PVDF membranes and probed using polyclonal antibodies against κ- ( C3 ) or α-chain (C4). Lanes: (1) control IgA2, (2) 225-IgA2-wt, 3) 225-IgA2-d471. ( D ) 225-IgA2-wt and –d471 producing cells were transfected with a pIRESpuro3 plasmid encoding human J-chain to allow the formation of stable dimeric IgA. Proteins were transferred onto PVDF membranes and stained using polyclonal antibodies against human α-chain. Lanes: (1) control IgA2, (2) purified monomeric 225-IgA2-wt, (3) purified monomeric 225-IgA2-d471, (4) 225-IgA2-wt containing SUP from CHO cells transfected with human J chain, (5) 225-IgA2-d471 containing SUP from CHO cells transfected with human J chain, (6) purified dimeric 225-IgA2-wt. ( E ) The composition of freshly prepared (E1), two (E2) and four (E3) year old preparations of 225-IgA2-wt (lane 1) and 225-IgA2-d471 (lane 2) was analyzed by analytical size exclusion chromatography on a Superdex200 10 × 300 column. (E4) Relative areas under the curve (rAUC) of monomeric (F M , elution volumes 10‒14 ml) and polymeric (F P , elution volumes 6.5–10 ml) IgA were calculated. ( F ) Thermal stability was analyzed by incubating antibodies at denaturing temperatures and measuring maintenance of functionality in chromium release assays using A431 as targets and freshly isolated human PMN as effector cells. Results are presented as “mean ± SEM” of “relative specific lysis [%]” of three independent experiments.
Non Conjugated Anti Human Iga2 Monoclonal Antibodies (Mabs), supplied by ICN Biomedicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+iga2+antibody/non+conjugated+anti+human+iga2+monoclonal+antibodies++mabs+/pmc02962958-188-27-34
Average 90 stars, based on 1 article reviews
non-conjugated anti-human iga2 monoclonal antibodies (mabs) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
OriGene iga2
Figure 1. Biochemical characterization of <t>225-IgA2-d471</t> and 225-IgA2-wt antibody. ( A ) Antibody content in supernatants was analyzed by ELISA, and specific production rates were calculated. ( B ) Affinity-purified antibodies were separated by size exclusion to isolate monomeric antibodies. ( C1 ) Purity of antibodies was analyzed by denaturing SDS-PAGE stained with silver nitrate. ( C2 ) Formation of non-native aggregates was analyzed using native-PAGE stained with Coomassie. Proteins were transferred onto PVDF membranes and probed using polyclonal antibodies against κ- ( C3 ) or α-chain (C4). Lanes: (1) control IgA2, (2) 225-IgA2-wt, 3) 225-IgA2-d471. ( D ) 225-IgA2-wt and –d471 producing cells were transfected with a pIRESpuro3 plasmid encoding human J-chain to allow the formation of stable dimeric IgA. Proteins were transferred onto PVDF membranes and stained using polyclonal antibodies against human α-chain. Lanes: (1) control IgA2, (2) purified monomeric 225-IgA2-wt, (3) purified monomeric 225-IgA2-d471, (4) 225-IgA2-wt containing SUP from CHO cells transfected with human J chain, (5) 225-IgA2-d471 containing SUP from CHO cells transfected with human J chain, (6) purified dimeric 225-IgA2-wt. ( E ) The composition of freshly prepared (E1), two (E2) and four (E3) year old preparations of 225-IgA2-wt (lane 1) and 225-IgA2-d471 (lane 2) was analyzed by analytical size exclusion chromatography on a Superdex200 10 × 300 column. (E4) Relative areas under the curve (rAUC) of monomeric (F M , elution volumes 10‒14 ml) and polymeric (F P , elution volumes 6.5–10 ml) IgA were calculated. ( F ) Thermal stability was analyzed by incubating antibodies at denaturing temperatures and measuring maintenance of functionality in chromium release assays using A431 as targets and freshly isolated human PMN as effector cells. Results are presented as “mean ± SEM” of “relative specific lysis [%]” of three independent experiments.
Iga2, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+iga2+antibody/Human+IgA2+(A2m2+Allotype+Specific)+Mouse+Monoclonal+Antibody/pm22777159-56-15-17
Average 90 stars, based on 1 article reviews
iga2 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

N/A
Rabbit polyclonal to IgA1 IgA2 Isotype Note: IgG Host Note: Rabbit Conjugation Note: Unconjugated Reactivity Note: Human Application Note: ELISA, IHC-P, IF/ICC
  Buy from Supplier

N/A
Human IgA2 mouse monoclonal antibody clone NI 512 A89 038 Biotin
  Buy from Supplier

Image Search Results


Figure 1. Biochemical characterization of 225-IgA2-d471 and 225-IgA2-wt antibody. ( A ) Antibody content in supernatants was analyzed by ELISA, and specific production rates were calculated. ( B ) Affinity-purified antibodies were separated by size exclusion to isolate monomeric antibodies. ( C1 ) Purity of antibodies was analyzed by denaturing SDS-PAGE stained with silver nitrate. ( C2 ) Formation of non-native aggregates was analyzed using native-PAGE stained with Coomassie. Proteins were transferred onto PVDF membranes and probed using polyclonal antibodies against κ- ( C3 ) or α-chain (C4). Lanes: (1) control IgA2, (2) 225-IgA2-wt, 3) 225-IgA2-d471. ( D ) 225-IgA2-wt and –d471 producing cells were transfected with a pIRESpuro3 plasmid encoding human J-chain to allow the formation of stable dimeric IgA. Proteins were transferred onto PVDF membranes and stained using polyclonal antibodies against human α-chain. Lanes: (1) control IgA2, (2) purified monomeric 225-IgA2-wt, (3) purified monomeric 225-IgA2-d471, (4) 225-IgA2-wt containing SUP from CHO cells transfected with human J chain, (5) 225-IgA2-d471 containing SUP from CHO cells transfected with human J chain, (6) purified dimeric 225-IgA2-wt. ( E ) The composition of freshly prepared (E1), two (E2) and four (E3) year old preparations of 225-IgA2-wt (lane 1) and 225-IgA2-d471 (lane 2) was analyzed by analytical size exclusion chromatography on a Superdex200 10 × 300 column. (E4) Relative areas under the curve (rAUC) of monomeric (F M , elution volumes 10‒14 ml) and polymeric (F P , elution volumes 6.5–10 ml) IgA were calculated. ( F ) Thermal stability was analyzed by incubating antibodies at denaturing temperatures and measuring maintenance of functionality in chromium release assays using A431 as targets and freshly isolated human PMN as effector cells. Results are presented as “mean ± SEM” of “relative specific lysis [%]” of three independent experiments.

Journal: mAbs

Article Title: Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2 m(1) antibody

doi: 10.4161/mabs.26396

Figure Lengend Snippet: Figure 1. Biochemical characterization of 225-IgA2-d471 and 225-IgA2-wt antibody. ( A ) Antibody content in supernatants was analyzed by ELISA, and specific production rates were calculated. ( B ) Affinity-purified antibodies were separated by size exclusion to isolate monomeric antibodies. ( C1 ) Purity of antibodies was analyzed by denaturing SDS-PAGE stained with silver nitrate. ( C2 ) Formation of non-native aggregates was analyzed using native-PAGE stained with Coomassie. Proteins were transferred onto PVDF membranes and probed using polyclonal antibodies against κ- ( C3 ) or α-chain (C4). Lanes: (1) control IgA2, (2) 225-IgA2-wt, 3) 225-IgA2-d471. ( D ) 225-IgA2-wt and –d471 producing cells were transfected with a pIRESpuro3 plasmid encoding human J-chain to allow the formation of stable dimeric IgA. Proteins were transferred onto PVDF membranes and stained using polyclonal antibodies against human α-chain. Lanes: (1) control IgA2, (2) purified monomeric 225-IgA2-wt, (3) purified monomeric 225-IgA2-d471, (4) 225-IgA2-wt containing SUP from CHO cells transfected with human J chain, (5) 225-IgA2-d471 containing SUP from CHO cells transfected with human J chain, (6) purified dimeric 225-IgA2-wt. ( E ) The composition of freshly prepared (E1), two (E2) and four (E3) year old preparations of 225-IgA2-wt (lane 1) and 225-IgA2-d471 (lane 2) was analyzed by analytical size exclusion chromatography on a Superdex200 10 × 300 column. (E4) Relative areas under the curve (rAUC) of monomeric (F M , elution volumes 10‒14 ml) and polymeric (F P , elution volumes 6.5–10 ml) IgA were calculated. ( F ) Thermal stability was analyzed by incubating antibodies at denaturing temperatures and measuring maintenance of functionality in chromium release assays using A431 as targets and freshly isolated human PMN as effector cells. Results are presented as “mean ± SEM” of “relative specific lysis [%]” of three independent experiments.

Article Snippet: Purified human myeloma IgA2 m(1) antibody was used as control IgA2 (Meridian Life Science).

Techniques: Enzyme-linked Immunosorbent Assay, Affinity Purification, SDS Page, Staining, Clear Native PAGE, Control, Transfection, Plasmid Preparation, Purification, Size-exclusion Chromatography, Isolation, Lysis

Figure 2. Fab-mediated effector functions were not impaired by the d471 mutation. ( A ) Binding of 225-IgA2-wt and –d471 to EGFR-expressing A431 cells was analyzed by indirect immunofluorescence analyses using anti-human kappa light chain directed secondary antibody. ( B ) Blocking of EGF binding was detected by FACS analyses treating A431 cells simultaneously with FITC-labeled EGF and excess of specific or nonspecific antibodies. ( C ) DiFi colon carcinoma cells were incubated with IgA2 antibodies for 72 h before viability was measured by MTS assay. Results are shown as “mean ± SEM” of “EGFR binding [RFI]” ( A ), “inhibition of EGF binding [%]” ( B ) and “cell viability [%]” ( C ) of five different experiments. Significant differences (p ≤ 0.001) between EGFR-specific and non-specific (control IgA2) antibodies are indicated by *, between mutant and wild type IgA2 by #.

Journal: mAbs

Article Title: Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2 m(1) antibody

doi: 10.4161/mabs.26396

Figure Lengend Snippet: Figure 2. Fab-mediated effector functions were not impaired by the d471 mutation. ( A ) Binding of 225-IgA2-wt and –d471 to EGFR-expressing A431 cells was analyzed by indirect immunofluorescence analyses using anti-human kappa light chain directed secondary antibody. ( B ) Blocking of EGF binding was detected by FACS analyses treating A431 cells simultaneously with FITC-labeled EGF and excess of specific or nonspecific antibodies. ( C ) DiFi colon carcinoma cells were incubated with IgA2 antibodies for 72 h before viability was measured by MTS assay. Results are shown as “mean ± SEM” of “EGFR binding [RFI]” ( A ), “inhibition of EGF binding [%]” ( B ) and “cell viability [%]” ( C ) of five different experiments. Significant differences (p ≤ 0.001) between EGFR-specific and non-specific (control IgA2) antibodies are indicated by *, between mutant and wild type IgA2 by #.

Article Snippet: Purified human myeloma IgA2 m(1) antibody was used as control IgA2 (Meridian Life Science).

Techniques: Mutagenesis, Binding Assay, Expressing, Immunofluorescence, Blocking Assay, Labeling, Incubation, MTS Assay, Inhibition, Control

Figure 3. FcαRI-binding and recruitment of myeloid effector cells. In ( A ), binding of 225-IgA2-wt and –d471 to BHK-21 cells co-transfected with human FcαRI and FcRγ was measured by indirect immunofluorescence using FITC-labeled anti-human kappa light chain directed secondary antibody. Efficiency of IgA2 antibodies in mediating ADCC against A431 targets cells was analyzed in chromium release assays using whole blood and increasing antibody concentrations ( B ). Next, increasing volumes of whole blood ( C ) and increasing ratios of isolated granulocytes ( D ), monocytes ( E ) and monocyte-derived macrophages ( F ) were used as effectors cells. Results are shown as “mean ± SEM” of “FcαRI binding [RFI %]” ( A ) or “specific lysis [%]” ( B–F ) of at least five independent experiments. Significant differences between EGFR-specific and control antibodies (control IgG1 in [ A ], control IgA2 in [ B‒F ]) are indicated by * ( P ≤ 0.001).

Journal: mAbs

Article Title: Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2 m(1) antibody

doi: 10.4161/mabs.26396

Figure Lengend Snippet: Figure 3. FcαRI-binding and recruitment of myeloid effector cells. In ( A ), binding of 225-IgA2-wt and –d471 to BHK-21 cells co-transfected with human FcαRI and FcRγ was measured by indirect immunofluorescence using FITC-labeled anti-human kappa light chain directed secondary antibody. Efficiency of IgA2 antibodies in mediating ADCC against A431 targets cells was analyzed in chromium release assays using whole blood and increasing antibody concentrations ( B ). Next, increasing volumes of whole blood ( C ) and increasing ratios of isolated granulocytes ( D ), monocytes ( E ) and monocyte-derived macrophages ( F ) were used as effectors cells. Results are shown as “mean ± SEM” of “FcαRI binding [RFI %]” ( A ) or “specific lysis [%]” ( B–F ) of at least five independent experiments. Significant differences between EGFR-specific and control antibodies (control IgG1 in [ A ], control IgA2 in [ B‒F ]) are indicated by * ( P ≤ 0.001).

Article Snippet: Purified human myeloma IgA2 m(1) antibody was used as control IgA2 (Meridian Life Science).

Techniques: Binding Assay, Transfection, Immunofluorescence, Labeling, Isolation, Derivative Assay, Lysis, Control

Figure 4. Glycosylation of wild type and d471-mutated IgA2 antibodies. Single clones producing 225-IgA2-wt and –d471 were cultured in tissue culture flasks (TCF), and glycosylation of affinity-purified antibodies was analyzed using lectin blots. Different sugar moieties were detected using biotinylated lectins specific for terminal galactosylation ( A1 ), α(1,6)-linked fucosylation ( A2 ), α-linked mannosylation ( A3 ), α(1,3)-linked mannosylation ( A4 ), N -acetylglucosamine ( A5 ), terminal sialic acid ( A6 ), and human α-chain as loading control ( A7 ). Lanes: 1. 225-IgA2-wt (CL1000 produced), 2. 225-IgA2-wt clone 1, 3. 225-IgA2-wt clone 2, 4. 225-IgA2-wt clone 3, 5. 225-IgA2-d471 (CL1000 produced), 6. 225-IgA2-d471 clone 1, 7. 225-IgA2-wt clone 2, 8. 225-IgA2-wt clone 3, 9. control IgA2. ( A8 ) To evaluate whether that glycosylation of wild type and mutant IgA2 antibodies was different, lectin blots were analyzed densitometrically using ImageJ software. Results are presented as “pixel density (dots per inch [dpi])” and significant differences between wild type and mutant IgA2 glycosylation are indicated by * ( P ≤ 0.001).

Journal: mAbs

Article Title: Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2 m(1) antibody

doi: 10.4161/mabs.26396

Figure Lengend Snippet: Figure 4. Glycosylation of wild type and d471-mutated IgA2 antibodies. Single clones producing 225-IgA2-wt and –d471 were cultured in tissue culture flasks (TCF), and glycosylation of affinity-purified antibodies was analyzed using lectin blots. Different sugar moieties were detected using biotinylated lectins specific for terminal galactosylation ( A1 ), α(1,6)-linked fucosylation ( A2 ), α-linked mannosylation ( A3 ), α(1,3)-linked mannosylation ( A4 ), N -acetylglucosamine ( A5 ), terminal sialic acid ( A6 ), and human α-chain as loading control ( A7 ). Lanes: 1. 225-IgA2-wt (CL1000 produced), 2. 225-IgA2-wt clone 1, 3. 225-IgA2-wt clone 2, 4. 225-IgA2-wt clone 3, 5. 225-IgA2-d471 (CL1000 produced), 6. 225-IgA2-d471 clone 1, 7. 225-IgA2-wt clone 2, 8. 225-IgA2-wt clone 3, 9. control IgA2. ( A8 ) To evaluate whether that glycosylation of wild type and mutant IgA2 antibodies was different, lectin blots were analyzed densitometrically using ImageJ software. Results are presented as “pixel density (dots per inch [dpi])” and significant differences between wild type and mutant IgA2 glycosylation are indicated by * ( P ≤ 0.001).

Article Snippet: Purified human myeloma IgA2 m(1) antibody was used as control IgA2 (Meridian Life Science).

Techniques: Glycoproteomics, Clone Assay, Cell Culture, Affinity Purification, Control, Produced, Mutagenesis, Software

Figure 5. Recruitment of myeloid effector cells by differently glycosylated IgA2 antibodies. The capacity of differently glycosylated wild type and d471-mutated IgA2 antibodies to mediate ADCC of human A431 tumor cells was analyzed in chromium release assays using isolated granulocytes or monocytes as effector cells. Results are shown as “mean ± SEM” of “specific lysis [%]” of at least three independent experiments.

Journal: mAbs

Article Title: Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2 m(1) antibody

doi: 10.4161/mabs.26396

Figure Lengend Snippet: Figure 5. Recruitment of myeloid effector cells by differently glycosylated IgA2 antibodies. The capacity of differently glycosylated wild type and d471-mutated IgA2 antibodies to mediate ADCC of human A431 tumor cells was analyzed in chromium release assays using isolated granulocytes or monocytes as effector cells. Results are shown as “mean ± SEM” of “specific lysis [%]” of at least three independent experiments.

Article Snippet: Purified human myeloma IgA2 m(1) antibody was used as control IgA2 (Meridian Life Science).

Techniques: Isolation, Lysis